ClinicalTrials.gg

Program

Cannabidiol

Also written as “GWP42003-P”, “Cannabidiol Oral Solution” and “CBD”.

Its studies are mostly in Epilepsy · Lennox Gastaut Syndrome · Epilepsies, Myoclonic · Seizures · Spasms, Infantile, led by 16 companies.

Furthest: phase 4, since Oct 17, 201964 company-led studies, 8 open or runningNext primary completion: Aug 1, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jazz Pharmaceuticals315 open or runningphase 4since Oct 17, 2019Oct 7, 2010Aug 1, 2027phase 4 · NCT05044819
INSYS Therapeutics50 open or runningphase 3since Dec 12, 2014Dec 12, 2014none ahead
Radius Pharmaceuticals50 open or runningphase 3since Jan 26, 2018Jul 22, 2016none ahead
Cardiol Therapeutics41 open or runningphase 3since Nov 2, 2020Nov 2, 2020none ahead
Pure Green40 open or runningphase 2since Sep 10, 2019Sep 10, 2019none ahead
Canopy Growth30 open or runningphase 2since Aug 29, 2019Aug 29, 2019none ahead
Botanix Pharmaceuticals20 open or runningphase 2since Jun 19, 2018Jun 19, 2018none ahead
Stero Biotechs20 open or runningphase 2since Mar 18, 2019Mar 18, 2019none ahead
Avecho Biotechnology11 open or runningphase 3since Apr 23, 2023Apr 23, 2023Sep 30, 2027phase 3 · NCT05840822
bod-australia10 open or runningphase 2since Dec 20, 2021Dec 20, 2021none ahead
dsm-firmenich10 open or runningphase 1since Aug 20, 2024Aug 20, 2024none ahead
empowerpharm-inc10 open or runningphase 2since Oct 26, 2022Oct 26, 2022none ahead
kalytera-therapeutics-israel-ltd10 open or runningphase 2since Feb 10, 2019Feb 10, 2019none ahead
laboratorio-elea-phoenix-s-a11 open or runningphase 2since Sep 30, 2024Sep 30, 2024none ahead
pure-green-pharmaceuticals-inc10 open or runningphase 2since Mar 2, 2023Mar 2, 2023none ahead
Tiamat Australia Pty10 open or runningphase 1since Feb 14, 2025Feb 14, 2025none ahead

Also a collaborator on its studies: jazz-pharmaceuticals-research-uk-limited and benuvia-therapeutics-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 45 studies since Mar 17, 2014.

  1. Mar 21, 2022Phase 1 study in Bone Diseases, MetabolicCanopy Growth · NCT05317013 · 2 enrolled · United States
  2. Aug 8, 2022Phase 2 study in PericarditisCardiol Therapeutics · NCT05494788 · 27 enrolled · United States
  3. Oct 26, 2022empowerpharm-inc's first study: phase 2 study in Phobia, SocialNew to empowerpharm-incempowerpharm-inc · NCT05600114 · 239 enrolled · United States
  4. Dec 24, 2022Phase 2 study in Menstrual DiscomfortCanopy Growth · NCT05679830 · 33 enrolled · United States
  5. Mar 2, 2023pure-green-pharmaceuticals-inc's first study: phase 2 study in Diabetic Peripheral Neuropathic PainNew to pure-green-pharmaceuticals-incpure-green-pharmaceuticals-inc · NCT05766969 · 52 enrolled · United States
  6. Apr 23, 2023Avecho Biotechnology's first study: phase 3 study in Sleep Initiation and Maintenance DisordersNew to Avecho BiotechnologyAvecho Biotechnology · NCT05840822 · 519 enrolled · Australia
  7. May 9, 2023Phase 4 study in SeizuresJazz Pharmaceuticals · NCT05864846 · 79 enrolled · United States, Canada, Poland and more
  8. Aug 20, 2024dsm-firmenich's first study: phase 1 study in CBD PharmacokineticsNew to dsm-firmenichdsm-firmenich · NCT06578455 · 32 enrolled · Canada
  9. Sep 30, 2024laboratorio-elea-phoenix-s-a's first study: phase 2 study in Parkinson DiseaseNew to laboratorio-elea-phoenix-s-alaboratorio-elea-phoenix-s-a · NCT06629389 · 88 planned · Argentina
  10. Nov 25, 2024Phase 3 study in PericarditisCardiol Therapeutics · NCT06708299 · 110 planned · United States, Canada, Greece and more
  11. Feb 14, 2025Tiamat Australia Pty's first study: phase 1 study in PharmacokineticsNew to Tiamat Australia PtyTiamat Australia Pty · NCT06854783 · 20 enrolled · Australia
  12. Nov 14, 2025Phase 1 study in SeizuresJazz Pharmaceuticals · NCT07233239 · 100 planned · United States
  13. Jul 20, 20262 phase 3 studiesJazz Pharmaceuticals · NCT07723976, NCT07723963
  14. Jul 22, 2026Phase 4 study in Lennox Gastaut SyndromeJazz Pharmaceuticals · NCT07728097 · 40 planned · United States

Ahead

  1. Aug 1, 2027Primary completion: phase 4 study in Lennox Gastaut SyndromeJazz Pharmaceuticals · NCT05044819
  2. Sep 30, 2027Primary completion: phase 3 study in Sleep Initiation and Maintenance DisordersAvecho Biotechnology · NCT05840822
  3. Nov 29, 2027Primary completion: phase 1 study in SeizuresJazz Pharmaceuticals · NCT07233239
  4. Aug 1, 2028Primary completion: phase 3 study in Myoclonic Epilepsy, JuvenileJazz Pharmaceuticals · NCT07723963

TargetBeta

CNR1 →read by rule
“Cannabinoid CB1 receptor negative allosteric modulator”ChEMBL 37, by rule

Other programs on CNR1

ProgramCompanyFurthest phaseStudies
RimonabantruleSanofiphase 338
DronabinolruleJazz Pharmaceuticalsphase 320
CRB-913rulecorbus-pharmaceuticals-incphase 11

Studies

The newest 60 of 64 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07728097Lennox Gastaut Syndrome · United States4Not yet recruitingJazz PharmaceuticalsDec 28, 202840
NCT07723976Developmental and Epileptic Encephalopathy (DEE)3Not yet recruitingJazz PharmaceuticalsSep 4, 2029120
NCT07723963Myoclonic Epilepsy, Juvenile · United States3RecruitingJazz PharmaceuticalsAug 1, 2028260
NCT07233239Seizures · United States1RecruitingJazz PharmaceuticalsNov 29, 2027100
NCT06854783Pharmacokinetics · Australia1CompletedTiamat Australia PtyOct 1, 202520
NCT06708299Pericarditis · United States, Canada, Greece and more3RecruitingCardiol TherapeuticsSep 21, 2026110
NCT06629389Parkinson Disease · Argentina2Recruitinglaboratorio-elea-phoenix-s-aNov 202588
NCT06578455CBD Pharmacokinetics · Canada1Completeddsm-firmenichNov 20, 202432
NCT05864846Seizures · United States, Canada, Poland and more4CompletedJazz PharmaceuticalsApr 6, 202679
NCT05840822Sleep Initiation and Maintenance Disorders · Australia3Active, not recruitingAvecho BiotechnologySep 30, 2027519
NCT05766969Diabetic Peripheral Neuropathic Pain · United States2UNKNOWNpure-green-pharmaceuticals-incDec 5, 202352
NCT05679830Menstrual Discomfort · United States2CompletedCanopy GrowthSep 23, 202133
NCT05600114Phobia, Social · United States2Completedempowerpharm-incDec 13, 2023239
NCT05494788Pericarditis · United States2CompletedCardiol TherapeuticsJun 15, 202427
NCT05317013Bone Diseases, Metabolic · United States1TerminatedCanopy GrowthSep 22, 20222
NCT05288283Epilepsy · United States, Italy3TerminatedJazz PharmaceuticalsSep 28, 20233
NCT05253417Parasomnias · Australia2Completedbod-australiaJul 7, 2023208
NCT05180240Acute Myocarditis · United States, Brazil, Canada and more2CompletedCardiol TherapeuticsJan 31, 2025109
NCT05044819Lennox Gastaut Syndrome · United States4Active, not recruitingJazz PharmaceuticalsAug 1, 2027154
NCT04992962Osteoarthritis, Knee · United States2UNKNOWNPure GreenOct 30, 202166
NCT04745026Autism Spectrum Disorder · United States, Australia, Canada and more2CompletedJazz PharmaceuticalsDec 21, 2023103
NCT04679545Diabetic Peripheral Neuropathic Pain · United States2UNKNOWNPure GreenMar 1, 202150
NCT04615949COVID-19 · United States, Brazil, Mexico3TerminatedCardiol TherapeuticsNov 30, 202290
NCT04485104Epilepsy · United States, Italy, Spain3TerminatedJazz PharmaceuticalsJan 28, 20253
NCT04421456Schizophrenia · United States, Poland, Serbia and more2TerminatedJazz PharmaceuticalsMar 16, 202295
NCT04252586Rett Syndrome · United States, Australia, Canada and more3TerminatedJazz PharmaceuticalsJun 9, 202121
NCT04439955Chronic Urticaria · Israel2CompletedStero BiotechsJul 30, 202115
NCT04193631Musculoskeletal Pain · United States1CompletedPure GreenDec 9, 201916
NCT04133480Lennox Gastaut Syndrome4WithdrawnJazz PharmaceuticalsDec 20210
NCT04088929Diabetic Neuropathies · United States2CompletedPure GreenNov 22, 201932
NCT04086342Phobia, Social · Canada2WithdrawnCanopy GrowthJan 26, 20210
NCT04129489Hepatitis, Autoimmune · Israel2TerminatedStero BiotechsMar 1, 20202
NCT03848832Rett Syndrome · United States, Italy, Spain and more3TerminatedJazz PharmaceuticalsJan 21, 202129
NCT03840512Prevention aGVHD · Australia, Israel2UNKNOWNkalytera-therapeutics-israel-ltdNov 15, 202236
NCT03824405Dermatitis, Atopic · United States, Australia, New Zealand2CompletedBotanix PharmaceuticalsJan 27, 2020200
NCT03573518Acne Vulgaris · United States, Australia2CompletedBotanix PharmaceuticalsAug 16, 2019368
NCT03458416Prader-Willi Syndrome · United States2TerminatedRadius PharmaceuticalsJul 31, 20192
NCT03421496Spasms, Infantile · United States3TerminatedRadius PharmaceuticalsMay 29, 20192
NCT03355300Epilepsy, Absence · United States2TerminatedRadius PharmaceuticalsJun 24, 201911
NCT03336242Epilepsy, Absence · United States2TerminatedRadius PharmaceuticalsMay 15, 201920
NCT02954887Spasms, Infantile · United States, Poland3CompletedJazz PharmaceuticalsJun 13, 20199
NCT02953548Spasms, Infantile · United States, Poland3CompletedJazz PharmaceuticalsMay 7, 20189
NCT02844933Prader-Willi Syndrome · United States2TerminatedRadius PharmaceuticalsJul 17, 20197
NCT02607904Epilepsy · Netherlands, Spain, Sweden2CompletedJazz PharmaceuticalsMay 27, 201930
NCT02607891Epilepsy · Netherlands, Spain, Sweden2CompletedJazz PharmaceuticalsSep 11, 201835
NCT02565108Epilepsy · Spain, United Kingdom2CompletedJazz PharmaceuticalsJul 21, 201620
NCT02564952Epilepsy · Spain, United Kingdom2CompletedJazz PharmaceuticalsJun 7, 201718
NCT02551731Spasms, Infantile · United States2TerminatedINSYS TherapeuticsSep 6, 20169
NCT02544763Tuberous Sclerosis · United States, Australia, Netherlands and more3CompletedJazz PharmaceuticalsJan 22, 2019224
NCT02544750Tuberous Sclerosis · United States3CompletedJazz PharmaceuticalsJun 11, 2021199
NCT02324673Seizures · United States2CompletedINSYS TherapeuticsMay 9, 201661
NCT02318602Seizures · United States3CompletedINSYS TherapeuticsJun 22, 201752
NCT02318563Epilepsies, Myoclonic3WithdrawnINSYS TherapeuticsJun 17, 20180
NCT02318537Lennox Gastaut Syndrome3WithdrawnINSYS TherapeuticsJun 30, 20180
NCT02224703Epilepsy · United States, Australia, Israel and more3CompletedJazz PharmaceuticalsApr 9, 2018199
NCT02224690Epilepsy · United States, Netherlands, Poland3CompletedJazz PharmaceuticalsMar 18, 2016171
NCT02224573Epilepsy3CompletedJazz PharmaceuticalsSep 24, 2020681
NCT02224560Epilepsy · United States, France, Spain and more3CompletedJazz PharmaceuticalsMay 19, 2016225
NCT02091375Epilepsy · United States, France, Poland and more3CompletedJazz PharmaceuticalsNov 26, 2015120
NCT02091206Epilepsy · United States, United Kingdom2CompletedJazz PharmaceuticalsMar 9, 201534

How it is read

Names in the registry

  • “GWP42003-P”, 17 entries
  • “Cannabidiol Oral Solution”, 10 entries
  • “Cannabidiol”, 7 entries
  • “CBD”, 5 entries
  • “GWP42003”, 4 entries

Codes read as this program: JZP926.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.